Kidney Precision Medicine Project Tissue Interrogation Sites (UG3/UH3)

RFA-DK-16-027
Kidney Precision Medicine Project Tissue Interrogation Sites (UG3/UH3)
Department of Health and Human Services
National Institutes of HealthDigital-Health-Infographic-08-636x412

Background

AKI and CKD impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Community feedback indicates that—despite significant effort from industry and academia—development of pharmacologic therapies for AKI and CKD has been hampered by non-predictive animal models, the inability to identify and prioritize human targets, the limited availability of human kidney biopsy tissue, and a poor understanding of AKI and CKD heterogeneity [Kidney Research National Dialogue 2014; AKI Outcomes Meeting 2015; Kidney Precision Medicine Meeting 2016]. Historically, AKI and CKD have been described as single, uniform diseases; however, growing consensus suggests that different disease pathways lead to different subgroups of AKI and CKD (AKIs and CKDs). Access to human kidney biopsy tissue is a critical first step to define disease heterogeneity and determine the precise molecular pathways that will facilitate identification of specific drug targets and ultimately enable individualized care for people with AKI and CKD.

Recent advances in multi-scale interrogation of human tissue and single cells have set the stage for precision medicine to be applied to AKI and CKD. The objectives of the KPMP are to ethically obtain and evaluate human kidney biopsies from participants with AKI or CKD, create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. The KPMP will be made up of three distinct, but highly interactive activities:

1.  Recruitment Sites: recruit people with AKI or CKD for longitudinal cohort studies that include a research kidney biopsy.

2.  Tissue Interrogation Sites: use and develop innovative technologies to analyze human kidney tissue (this FOA).

3.  Central Hub: aggregate, analyze and visualize all data and samples, and provide scientific, infrastructure and administrative support for the entire KPMP.

All data and samples from the RS and TIS will go to the CH. In addition to an Administrative Core (AC), the CH will have a Data and samples Coordinating Center (DCC) and a Data Visualization Center (DVC). The DCC will perform standard clinical data assessments (e.g., patient data reports, recruitment tables, observational study reports), whereas the DVC will perform digital pathological assessments and create a kidney tissue atlas (incorporating data and images generated by the RS and TIS) to help define disease subgroups and identify critical cells, pathways and targets for novel therapies. The DVC will also manage a KPMP website to facilitate the sharing of all de-identified data and samples with the broader research community.

While kidney tissue from transplant, nephrectomy, and autopsy will be used to optimize tissue interrogation methods, these do not provide the quality and diversity of tissue to meet all of the KPMP objectives. The KPMP requires research kidney biopsies (or clinical biopsies with research core(s); collectively called research kidney biopsies throughout this document) linked to longitudinal clinical phenotypic data and biosamples.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DK-16-027
Funding Opportunity Title: Kidney Precision Medicine Project Tissue Interrogation Sites (UG3/UH3)
Opportunity Category: Discretionary
Opportunity Category Explanation:  
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:  
Expected Number of Awards:  
CFDA Number(s): 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Aug 17, 2016
Last Updated Date: Aug 17, 2016
Original Closing Date for Applications: Dec 06, 2016  
Current Closing Date for Applications: Dec 06, 2016  
Archive Date: Jan 06, 2017
Estimated Total Program Funding:  
Award Ceiling:  
Award Floor:

Eligibility

Eligible Applicants: Independent school districts
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
City or township governments
Special district governments
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) requests applications for the  (KPMP) Tissue Interrogation Sites (TIS) to use and develop innovative technologies to analyze human kidney tissue. The TIS will collaborate with the KPMP Recruitment Sites and Central Hub to obtain and evaluate kidney biopsies from participants with acute kidney injury and chronic kidney disease, create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. Applicant teams should have documented experience with a current state-of-the-art method that can be used or adapted to interrogate human kidney tissue. The initial UG3 exploratory phase will be used to demonstrate that the site can interrogate existing tissue samples and small numbers of new biopsies. The UG3 phase will also encourage the development of next generation tissue interrogation technologies that probe the structural, functional and molecular complexities of kidney tissue. UG3 projects that have met their milestones will be administratively considered by the NIDDK and prioritized for transition to the UH3 implementation phase. UH3 awards will support further validation, scale-up and technology development. Applicants must address both the UG3 and UH3 phases. This FOA is intended to support only human studies and applications that include animal or model systems are not responsive.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-027.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s